Nahum Wood’s Post

This is worth exploring: In a new study, First Ascent Biomedical used a combination of #AI, DNA sequencing, mutation mapping and drug sensitivity testing to help oncologists and clinicians develop personalized treatments for six pediatric cancer patients. Oncologists and clinicians were able to use this information to produce guided treatments much faster than if they had only done genomic profiling. Most importantly, five of the six patients showed strong improvements in their progression-free survival. Drug sensitivity testing isn’t new. What is new is using AI to turn test results into actionable information—quickly. While this study needs to be replicated with much larger samples, I hope it encourages us all to think about how adding AI to other approaches can transform our work.  #precisionmedicine #oncology  https://lnkd.in/dzGwVpTv  

The identification of treatments that selectively co-inhibit cancer cell populations (clones) remains a challenge. Due to the massive number of possible drug-dose combinations, an exhaustive exploration of the combinatorial space is experimentally unfeasible, especially considering the scarcity of patient cells. scTherapy is a novel machine learning approach that leverages single-cell transcriptomic profiles to identify multi-targeting treatment options for individual patients with hematological cancers or solid tumors. This approach and the model have recently been published in Nature Communications by Tero Aittokallio, Aleksandr Ianevski, Kristen Michelle Nader and colleagues. The study was done in collaboration with the researchers from Biotech Research & Innovation Centre (BRIC), University of Copenhagen, Helsinki University Central Hospital, University of Helsinki (Helsinki Institute of Life Science (HiLIFE) and Faculty of Medicine), and iCAN - Digital Precision Cancer Medicine Flagship project. Congratulations! Nordic EMBL Partnership for Molecular Medicine #CancerResearch #MachineLearning #PrecisionMedicine #transcriptomics #SingleCellAnalytics

Preclinical Advances in LNP-CRISPR Therapeutics for Solid Tumor Treatment A recent review in Cells titled "Preclinical Advances in LNP-CRISPR Therapeutics for Solid Tumor Treatment" by Shuting Wang, Yuxi Zhu, Shi Du, and Yunsi Zheng presents a significant leap forward in cancer treatment. This detailed analysis reveals how lipid nanoparticles (LNPs) can enhance the delivery and efficacy of CRISPR-Cas9 gene-editing technology, offering a promising avenue for targeting solid tumors. 𝑻𝒉𝒆 𝑹𝒐𝒍𝒆 𝒐𝒇 𝑳𝑵𝑷𝒔 𝒊𝒏 𝑮𝒆𝒏𝒆 𝑬𝒅𝒊𝒕𝒊𝒏𝒈 The authors highlight the advantages of LNPs over traditional delivery systems, emphasizing their biocompatibility, safety, and precision. LNPs encapsulate CRISPR components, ensuring targeted delivery to tumor cells while minimizing off-target effects. This innovation addresses one of the major hurdles in CRISPR technology: efficient and specific delivery to tumor sites. 𝑻𝒓𝒂𝒏𝒔𝒇𝒐𝒓𝒎𝒊𝒏𝒈 𝑺𝒐𝒍𝒊𝒅 𝑻𝒖𝒎𝒐𝒓 𝑻𝒉𝒆𝒓𝒂𝒑𝒚 The review showcases pivotal preclinical studies where LNP-CRISPR systems have been used to disrupt oncogenic pathways, leading to significant tumor regression. These studies underscore the potential of this combined approach to revolutionize cancer treatment by precisely targeting and editing cancer-related genes. 𝑭𝒓𝒐𝒎 𝑩𝒆𝒏𝒄𝒉 𝒕𝒐 𝑩𝒆𝒅𝒔𝒊𝒅𝒆 The authors provide a critical analysis of the clinical potential and challenges of LNP-CRISPR systems. They discuss the need for further research and innovative trial designs to translate these preclinical successes into effective clinical therapies. The review emphasizes the importance of interdisciplinary collaboration to advance these groundbreaking treatments. This seminal work calls for the scientific community to harness the power of LNP-CRISPR technology to develop targeted, personalized cancer therapies. #GeneEditing #CRISPR #LipidNanoparticles #CancerTherapy #OncologyInnovation #BiomedicalResearch #ClinicalOncology #MedicalScience #TranslationalMedicine #HealthcareInnovation #CancerBiology #ImmunologyResearch

#ICYMI Multiple myeloma is a complex form of plasma cell cancer that is currently untreatable. With approximately 200,000 new diagnoses each year globally, with a 100% relapse rate and 54% five-year overall survival rate, it continues to pose a significant challenge to modern medicine. In this blog, learn about the complex nature of this heterogeneous disease, and how single-cell analysis is providing valuable insights into potential drug targets and pathways to potentially enable therapy development. Read it here 👉 https://lnkd.in/g8B6ZYEG #blog #multiplemyeloma #drugdevelopment #drugdiscovery #singlecellanalysis #singlecell #multiomics

When (especially) data storage and financial accessibility issues (not only the cost to companies) are solved, WGS will be the ultimate "CDx", hopefully together with other omics data. The key findings below may be provided by some targeted panels; yet I think WGS (plus whole transcriptome) could improve the results and provide answers to more questions. We could also utilize the precious clinical samples to their maximum. ----- "WGS was supportive in ~81% of the cases conducted for clinical clarity. WGS provided information on the resistance/sensitivity mechanism (II-1), tumor origin (II-2), and evaluation of familial cancer patients (II-3)." https://lnkd.in/gvQmYNYP

I’m thrilled to announce the completion of our recent project on topic, the design and evaluation of PI3K inhibitors as potential anticancer agents. This work integrates cutting-edge computational techniques, including docking, ADMET profiling, pharmacophore modeling, and MD simulations, with in vitro anticancer activity assessments. Our study focuses on the development of novel PI3K inhibitors, combining computational insights to enhance understanding of their mechanisms and improve therapeutic efficacy. The journey has been challenging yet rewarding, paving the way for advancements in targeted cancer therapies. This is a step forward in the fight against cancer, leveraging computational and experimental synergy to design more effective and specific treatments. 🔗link: https://lnkd.in/gbGY2_mB 📢 Feel free to connect or reach out if you're interested in discussing the work or potential collaborations. #Research #DrugDiscovery #ComputationalBiology #AnticancerAgents #TargetedTherapies #PI3KInhibitors #Elsevier

More and more tissue-agnostic therapeutic options are being approved by the FDA for clinical use. The therapies target various genomic alterations, and their combinations that lead to cancer progression. Currently, those alterations are best detected by large NGS panels, also called “molecular microscope”. In this paper authors list currently available target/drug combinations (based on mutations, fusions/rearrangements, and microsatellite instability), illustrate emerging tissue-agnostic targets, and invite to expand search for agnostic therapeutics for all cancer types, beyond DNA-based biomarkers #cancermanagment #tissueagnostic

How Multi-Omics Is Empowering The Discovery Of Cancer Biomarkers

Precision medicine is transforming cancer treatment, moving from traditional approaches to therapies tailored to the genetic makeup of each patient’s tumor. Discover how umbrella and basket trials are advancing targeted therapies for more effective, individualised care. #PrecisionMedicine #CancerResearch #TargetedTherapies

This is the future. MI Cancer Seek is now the first US FDA-approved, combined whole exome sequencing/whole transcriptome sequencing (WES/WTS)-based NGS assay with FDA-approved indications for adults and pediatric patients. 8 CDx claims and tumor profiling claims approved - and many more to come. This is the premiere CDx option for biopharma - regardless of your biomarker(s)/patient selection strategy and/or need to pivot to address resistance or combination opportunities...we got you covered. It's all here, why risk missing something? One test w/ 23,000+ genes, DNA and RNA, and unmatched commercial testing scale. Let's go make precision medicine a reality for patients together. Caris Life Sciences #MICancerSeek #CDx #patientcare #diagnostics #precisionmedicine https://lnkd.in/es8MHBJs